GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>I have no basis to rebut your guess of 2013 as the market launch date for factorVIIa, but this seems rather gloomy estimate.<

Dr. Cox said 2009 was the earliest rhFVIIa could enter the clinic. Four years from the start of phase-1 to a product launch seems about right to include a realistic amount of time for enrolling patients, treating patients, analyzing data, designing phase-2 and phase-3 trials, preparing a BLA, and regulatory review. A gloomy forecast would IMO be considerably longer.